Merian Ranjbaryan, Peter Weisenseel, Syrus Alexander Karsai
{"title":"托法替尼治疗斑秃的疗效：幸运拳还是强力治疗？","authors":"Merian Ranjbaryan, Peter Weisenseel, Syrus Alexander Karsai","doi":"10.4103/ijt.ijt_101_24","DOIUrl":null,"url":null,"abstract":"<p><p>This article presents the case of a 31-year old patient with alopecia areata, who after two subsequent treatments with Janus kinase-inhibitors Baricitinib and Abrocitinib, achieved therapeutic success after using tofacitinib. This case raises the question, whether tofacitinib could be a valid treatment option for the future.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"17 3","pages":"245-247"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674502/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Tofacitinib in Alopecia Areata - Lucky Punch or Robust Treatment Option?\",\"authors\":\"Merian Ranjbaryan, Peter Weisenseel, Syrus Alexander Karsai\",\"doi\":\"10.4103/ijt.ijt_101_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This article presents the case of a 31-year old patient with alopecia areata, who after two subsequent treatments with Janus kinase-inhibitors Baricitinib and Abrocitinib, achieved therapeutic success after using tofacitinib. This case raises the question, whether tofacitinib could be a valid treatment option for the future.</p>\",\"PeriodicalId\":14417,\"journal\":{\"name\":\"International Journal of Trichology\",\"volume\":\"17 3\",\"pages\":\"245-247\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674502/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Trichology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijt.ijt_101_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/11/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Trichology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijt.ijt_101_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Efficacy of Tofacitinib in Alopecia Areata - Lucky Punch or Robust Treatment Option?
This article presents the case of a 31-year old patient with alopecia areata, who after two subsequent treatments with Janus kinase-inhibitors Baricitinib and Abrocitinib, achieved therapeutic success after using tofacitinib. This case raises the question, whether tofacitinib could be a valid treatment option for the future.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
